Coesisting inflammatory skin diseases: Tildrakizumab to control psoriasis and omalizumab for urticaria. Issue 4 (15th February 2022)

• Record Type: Journal Article
• Authors: Diluvio, Laura; Pensa, Chiara; Piccolo, Arianna; Lanna, Caterina; Bianchi, Luca; Campione, Elena
• Is Part Of: Dermatologic therapy. Volume 35:Issue 4(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-02-15
• Subjects: chronic spontaneous urticaria -- dual biologic therapy -- omalizumab -- psoriasis -- tildrakizumab; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.15359
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: In Western countries, the number of individuals suffering from an autoimmune condition is constantly growing and often patients suffering from autoimmune disease are susceptible to developing a second autoimmune disorder. We report a case of an adult female patient affected by psoriasis vulgaris and treated with tildrakizumab, a humanized monoclonal antibody targeting interleukin‐23, who later developed chronic spontaneous urticaria and started omalizumab, a humanized antibody to IgE, showing a favorable outcome. We speculate that the two combined therapies have restored the cytokine balance bringing it toward tolerance and remission of the two pathologies. It is conceivable that tildrakizumab may have a synergic action with omalizumab in the treatment of urticaria in patients affected by both psoriasis and urticaria. Our case and the study of the mechanisms of action of the two drugs suggest how the two therapies can act with an interlocking mechanism in achieving the final therapeutic effect.